Researchers have identified metabolic factors in plasma that influence the outcomes of cancer immunotherapy. The findings suggest a connection between certain metabolites, potentially derived from the microbiota, and the effectiveness of immunotherapy treatments. Studies are exploring the role of these metabolic determinants in cancer treatment, including their potential as biomarkers for diagnosis and personalized therapy.